Development of a physiologically based pharmacokinetic model for levetiracetam in patients with renal impairment to guide dose adjustment based on steady-state peak/trough concentrations

References

• Beau-Lejdstrom R, Hong LS, Garcia de Albeniz X, Floricel F, Lorenzen J, Bonfitto F, Kalilani L, Loesch C, Luscombe G, Perez-Gutthann S, et al. 2022. Incidence of acute renal failure in patients using levetiracetam versus other antiseizure medications: a voluntary post-authorization safety study. Drug Saf. 45(7):781–790. doi: 10.1007/s40264-022-01193-0.
   PubMed Web of Science ®Google Scholar
• Bou Nasif M, Varade S, Koubeissi MZ. 2021. Multifocal myoclonus as a presentation of levetiracetam toxicity. Clin Neurophysiol Pract. 6:281–284. doi: 10.1016/j.cnp.2021.10.004.
   PubMedGoogle Scholar
• Brockmöller J, Thomsen T, Wittstock M, Coupez R, Lochs H, Roots I. 2005. Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (child-pugh classes A, B, and C): characterization by dynamic liver function tests. Clin Pharmacol Ther. 77(6):529–541. doi: 10.1016/j.clpt.2005.02.003.
   PubMed Web of Science ®Google Scholar
• Chaijamorn W, Charoensareerat T, Rungkitwattanakul D, Phunpon S, Sathienluckana T, Srisawat N, Pattharachayakul S. 2021. Levetiracetam dosing in patients receiving continuous renal replacement therapy. Epilepsia. 62(9):2151–2158. doi: 10.1111/epi.16971.
   PubMed Web of Science ®Google Scholar
• Franchetti Y, Nolin TD. 2020. Dose optimization in kidney disease: opportunities for PBPK modeling and simulation. J Clin Pharmacol. 60 Suppl 1: s 36–S51.
   Web of Science ®Google Scholar
• Li X, Liang E, Hong X, Han X, Li C, Wang Y, Wang Z, Zheng A. 2021. In vitro and in vivo bioequivalence study of 3d-printed instant-dissolving levetiracetam tablets and subsequent personalized dosing for Chinese children based on physiological pharmacokinetic modeling. Pharmaceutics. 14(1):20. doi: 10.3390/pharmaceutics14010020.
   PubMed Web of Science ®Google Scholar
• Li ZR, Wang CY, Zhu X, Jiao Z. 2021. Population pharmacokinetics of levetiracetam: a systematic review. Clin Pharmacokinet. 60(3):305–318. doi: 10.1007/s40262-020-00963-2.
   PubMed Web of Science ®Google Scholar
• Lin W, Chen Y, Unadkat JD, Zhang X, Wu D, Heimbach T. 2022. Applications, challenges, and outlook for PBPK modeling and simulation: a regulatory, industrial and academic perspective. Pharm Res. 39(8):1701–1731. doi: 10.1007/s11095-022-03274-2.
   PubMed Web of Science ®Google Scholar
• Liu SJ, Chen D, Yin JG, Chu JH, Xu MJ, Liu F, Dai GL, Xiong NN, Ju WZ. 2017. Comparison of the pharmacokinetics of levetiracetam injection and levetiracetam tablets in human. J Clin Pharmacol. 22(3):294–298.
   Google Scholar
• Liu WX, Ding Y, Jia YY, Lu CT, Ding LK, Yang J, Liang H, Yang L, Wen AD. 2012. Pharmacokinetics of levetiracetam tablets in healthy volunteers. Chin J Clin Pharmacol. 28:271–274.
   Google Scholar
• Lukacova V, Goelzer P, Reddy M, Greig G, Reigner B, Parrott N. 2016. A physiologically based pharmacokinetic model for ganciclovir and its prodrug valganciclovir in adults and children. Aaps J. 18(6):1453–1463. doi: 10.1208/s12248-016-9956-4.
   PubMed Web of Science ®Google Scholar
• Ma T, Qian JH, Zhu XG, Tong XH, Gao S, Jiang ZW. 2007. Pharmacokinetics of levetiracetam in healthy volunteers. Chin Hosp Pharm J. 27:858–861.
   Google Scholar
• Nicolas J-M, Hannestad J, Holden D, Kervyn S, Nabulsi N, Tytgat D, Huang Y, Chanteux H, Staelens L, Matagne A, et al. 2016. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia. 57(2):201–209. doi: 10.1111/epi.13267.
   PubMed Web of Science ®Google Scholar
• Odi R, Bibi D, Wager T, Bialer M. 2020. A perspective on the physicochemical and biopharmaceutic properties of marketed antiseizure drugs-From phenobarbital to cenobamate and beyond. Epilepsia. 61(8):1543–1552. doi: 10.1111/epi.16597.
   PubMed Web of Science ®Google Scholar
• Patsalos PN. 2004. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 43(11):707–724. doi: 10.2165/00003088-200443110-00002.
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E. 2008. Antiepileptic drugs–best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 49(7):1239–1276. doi: 10.1111/j.1528-1167.2008.01561.x.
   PubMed Web of Science ®Google Scholar
• Powell G, Logan J, Kiri V, Borghs S. 2019. Trends in antiepileptic drug treatment and effectiveness in clinical practice in England from 2003 to 2016: a retrospective cohort study using electronic medical records. BMJ Open. 9(12):e032551. doi: 10.1136/bmjopen-2019-032551.
   PubMed Web of Science ®Google Scholar
• Rhee S-J, Shin J-W, Lee S, Moon J, Kim T-J, Jung K-Y, Park K-I, Lee S-T, Jung K-H, Yu K-S, et al. 2017. Population pharmacokinetics and dose-response relationship of levetiracetam in adult patients with epilepsy. Epilepsy Res. 132:8–14. doi: 10.1016/j.eplepsyres.2017.02.011.
   PubMed Web of Science ®Google Scholar
• Sedogawa H, Watanabe N, Hirose Y, Mizouchi N, Shimagaki S, Yamaguchi H, Hirose Y. 2022. Levetiracetam poisoning with acute kidney injury treated with hemodialysis: a case report. Medicine (Baltimore). 101(39):e30884. doi: 10.1097/MD.0000000000030884.
   PubMed Web of Science ®Google Scholar
• Shen C, Shao W, Wang W, Sun H, Wang X, Geng K, Wang X, Xie H. 2023. Physiologically based pharmacokinetic modeling of levetiracetam to predict the exposure in hepatic and renal impairment and elderly populations. CPT Pharmacometrics Syst Pharmacol. 12(7):1001–1015. doi: 10.1002/psp4.12971.
   PubMedGoogle Scholar
• Spengler DC, Montouris GD, Hohler AD. 2014. Levetiracetam as a possible contributor to acute kidney injury. Clin Ther. 36(8):1303–1306. doi: 10.1016/j.clinthera.2014.06.002.
   PubMed Web of Science ®Google Scholar
• Strolin Benedetti M, Whomsley R, Nicolas JM, Young C, Baltes E. 2003. Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers. Eur J Clin Pharmacol. 59(8-9):621–630. doi: 10.1007/s00228-003-0655-6.
   PubMed Web of Science ®Google Scholar
• Thurman DJ, Faught E, Helmers S, Kim H, Kalilani L. 2019. New-onset lesional and nonlesional epilepsy in the US population: patient characteristics and patterns of antiepileptic drug use. Epilepsy Res. 157:106210. doi: 10.1016/j.eplepsyres.2019.106210.
   PubMed Web of Science ®Google Scholar
• Vulliemoz S, Iwanowski P, Landis T, Jallon P. 2009. Levetiracetam accumulation in renal failure causing myoclonic encephalopathy with triphasic waves. Seizure. 18(5):376–378. doi: 10.1016/j.seizure.2009.01.006.
   PubMed Web of Science ®Google Scholar
• Wang M, Wang M, Zhang Q, Zong S, Lv C. 2018. Pharmacokinetics and safety of levetiracetam extended-release tablets and relative bioavailability compared with immediate-release tablets in healthy Chinese subjects. Eur J Drug Metab Pharmacokinet. 43(4):405–413. doi: 10.1007/s13318-018-0461-2.
   PubMed Web of Science ®Google Scholar
• Weir MR. 2021. Managing anemia across the stages of kidney disease in those hyporesponsive to erythropoiesis-stimulating agents. Am J Nephrol. 52(6):450–466. doi: 10.1159/000516901.
   PubMedGoogle Scholar
• Yamamoto J, Toublanc N, Kumagai Y, Stockis A. 2014. Levetiracetam pharmacokinetics in Japanese subjects with renal impairment. Clin Drug Investig. 34(11):819–828. doi: 10.1007/s40261-014-0237-7.
   PubMed Web of Science ®Google Scholar
• Yang Y, Chen Y, Wang L, Xu S, Fang G, Guo X, Chen Z, Gu Z. 2022. PBPK modeling on organs-on-chips: an overview of recent advancements. Front Bioeng Biotechnol. 10:900481. doi: 10.3389/fbioe.2022.900481.
   PubMed Web of Science ®Google Scholar
• Yau K, Burneo JG, Jandoc R, McArthur E, Muanda FT, Parikh CR, Wald R, Weir MA, Garg AX. 2019. Population-based study of risk of AKI with levetiracetam. Clin J Am Soc Nephrol. 14(1):17–26. doi: 10.2215/CJN.07490618.
   PubMed Web of Science ®Google Scholar